Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Net Income towards Common Stockholders: 2013-2025

Historic Net Income towards Common Stockholders for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Sep 2025 value amounting to $17.4 million.

  • Amphastar Pharmaceuticals' Net Income towards Common Stockholders fell 57.09% to $17.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.9 million, marking a year-over-year decrease of 35.76%. This contributed to the annual value of $148.4 million for FY2024, which is 8.91% up from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Net Income towards Common Stockholders is $17.4 million, which was down 44.09% from $31.0 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Net Income towards Common Stockholders peaked at $49.6 million during Q3 2023, and registered a low of $4.0 million during Q1 2021.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Net Income towards Common Stockholders value was $31.0 million (recorded in 2025), while the average stood at $32.6 million.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Net Income towards Common Stockholders skyrocketed by 703.36% in 2021, and later tumbled by 57.09% in 2025.
  • Quarterly analysis of 5 years shows Amphastar Pharmaceuticals' Net Income towards Common Stockholders stood at $20.0 million in 2021, then surged by 46.51% to $29.3 million in 2022, then rose by 14.09% to $33.4 million in 2023, then dropped by 21.40% to $26.2 million in 2024, then slumped by 57.09% to $17.4 million in 2025.
  • Its last three reported values are $17.4 million in Q3 2025, $31.0 million for Q2 2025, and $25.3 million during Q1 2025.